La chaîne d'options affiche les données clés des options sur actions de Shuttle Pharmaceuticals à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Shuttle Pharmaceuticals..

Shuttle Pharmaceuticals (NASDAQ:SHPH) Stock, Chaîne d'Options

Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings Inc is a clinical stage pharmaceutical company leveraging our proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments by leveraging insights into the pillars of cancer therapy: surgery, radiation therapy, chemotherapy, and immunotherapy.

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals Holdings Inc

SIHUAN PHARM HOLDINGS GP by Sihuan Pharmaceutical Holdings Group Ltd.

Sihuan Pharmaceutical Holdings Group Ltd

SIHUAN PHARM HLDGS ADR by Sihuan Pharmaceutical Holdings Group Ltd.

<a>Deere &amp; Co. </a>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) shares inched higher in early trading on Friday, after the company reported <a href="https://www.benzinga.com/24/11/42119233/crude-oil-gains-15-deere-posts-better-than-expected-earnings">upbeat fiscal fourth-quarter results</a>.
The company reported its results amid an <a href="https://www.benzinga.com/earnings">exciting earnings season</a>. Here are some key analyst takeaways.
<h1 class="wp-block-heading">Goldman Sachs On Deere &amp; Co.</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58ac6423b85e930001e63864/jerry-revich">Analyst Jerry Revich</a> maintained a Buy rating while raising the price target from $466 to $504.
Deere's fiscal fourth-quarter results revealed sa ignificant inventory destock of $2.6 billion "to bring dealer inventories to levels approaching prior trough," Revich said in a note. The used agricultural machinery market showed "signs of stabilization," as inventories down 1% over the past six months, he added.
The company's initial 2025 guidance reflects "40%+ decremental margins vs. 36% in 4Q24 and 36% for the full year," the analyst wrote. In precision agriculture, adoption rates have continued to rise across Deere's portfolio and revenues in this business could reach around $5 billion this year, he further stated.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
<h1 class="wp-block-heading">Oppenheimer On Deere &amp; Co.</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/6033dff0bb72670001bd2ade/kristen-owen">Analyst Kristen Owen</a> reiterated an Outperform rating while lifting the price target from $448 to $477.
Deere reported earnings of $4.55 per share on revenues of $11,143 million, higher than consensus of $3.87 per share and $11,052M, respectively, Owens said. "DE executed against its targeted underproduction in F4Q, enabling it to enter FY25 from a position of relative strength," he added.
The outlook is still concerning, with global agriculture fundamentals likely to deteriorate further in 2025, the analyst stated. "That said, the guide embeds an outlook for production cadence converging with demand, muted but positive price and price/cost, and solid cost execution," he further wrote.
<h1 class="wp-block-heading">BMO Capital Markets On Deere &amp; Co.</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5981fdcac1f558000155e852/joel-jackson">Analyst</a><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5981fdcac1f558000155e852/joel-jackson"> Joel Jackson</a> reaffirmed a Market Perform rating and a price target of $400.
The company's net income guidance range of $5 billion to $5.5 billion represents a contraction of around 50% from the 2023 peak, Jackson said. Management's commentary suggested performance could turn flattish or positive "at some point" in the second half of fiscal 2025, he added.
"Used equipment dynamic still normalizing for 1-2 year old combines/tractors in N. America," the analyst wrote. He further stated that fiscal 2025 earnings trough is expected to be below $20 per share.
DE Price Action: Shares of Deere &amp; Co. had risen by 1.46% to $443.92 at the time of publication on Friday.
Read More: • <a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a>
Photo: Shutterstock

Earnings Beats

Price Target

Reiteration

Analyst Ratings

Movers

Trading Ideas

Deere Posts Q4 Beat: 2025 Outlook Isn't Rosy But Company Has 'Relative Strength,' Analysts Say

Jake Paul was victorious in <a href="https://www.benzinga.com/general/sports/24/11/42022601/mike-tyson-vs-jake-paul-netflixs-explosive-boxing-event-ends-with-pauls-victory">Friday&#8217;s highly anticipated Netflix boxing match against Mike Tyson</a> and his real estate portfolio seems to outshine the boxing legend&#8217;s holdings too. The 27-year-old YouTuber-turned-boxer won unanimously and bought a $16 million compound that dwarfs Tyson's Nevada residence.
Don't Miss:
<ul>
<li>Invest in $20+ trillion home equity market today across cities like Austin, Miami, and Los Angeles through a <a href="https://www.benzinga.com/money/nada-cityfunds">unique 5-year term fund targeting a 14-20% IRR with minimums as low as $2,500</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
</ul>
Paul's recently acquired estate in Dorado, Puerto Rico, shows the social media star's success outside the ring. The eight-bedroom, eight-bathroom compound underwent $2.1 million in renovations after its 2023 purchase. In a recent YouTube tour titled &#8220;My new $20,000,000 house tour,&#8221; Paul highlighted his changes, including a redesigned entrance for improved energy flow.
According to Realtor.com, the property includes several distinctive amenities, such as a 40-person hot tub and dedicated office space for Paul&#8217;s content production team. His garage also received a custom makeover to accommodate his growing car collection.
By comparison, Tyson's real estate footprint appears modest. The former heavyweight champion's current residence, a $2.5 million mansion in Henderson, Nevada, has appreciated to an estimated $4.7 million, according to Realtor.com. The 8,000-square-foot home, where he lives with his wife, Lakiha Spicer and their children, has six bedrooms and six bathrooms.
Trending: This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a>
According to the report, Tyson's real estate history includes a previous 19,500-square-foot estate in Southington, Ohio, which he sold for $1.3 million during financial difficulties in the late 1990s. The 58-acre property's subsequent owner never occupied it, serving time in prison for money laundering.
The record-breaking<a href="https://www.benzinga.com/24/11/42025252/jake-paul-vs-mike-tyson-boxing-match-sets-record-breaking-night-for-netflix"> boxing match</a>, which earned Paul roughly $40 million and Tyson $20 million, further widens the wealth gap between the two fighters. According to CBS News, Paul said he wanted to fight again after the victory, targeting a championship title within two years. "I truly believe in my skills, my ability and my power," he said, setting his sights on the cruiserweight division.
While Tyson acknowledged the loss gracefully, posting &#8220;This is one of those situations when you lost but still won&#8221; on X, formerly Twitter.
Read Next:
<ul>
<li>Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a></li>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
</ul>

Real Estate

Netflix Boxing Battle Decided In The Ring, But Paul's $16M Mansion Takes The Real Estate Crown

Investors with a lot of money to spend have taken a bearish stance on ASML Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ASML, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 40 uncommon options trades for ASML Holding.
This isn't normal.
The overall sentiment of these big-money traders is split between 37% bullish and 50%, bearish.
Out of all of the special options we uncovered, 17 are puts, for a total amount of $1,038,822, and 23 are calls, for a total amount of $1,378,563.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $600.0 to $960.0 for ASML Holding over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for ASML Holding's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across ASML Holding's significant trades, within a strike price range of $600.0 to $960.0, over the past month.
<h3>ASML Holding Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732293644_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASML</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$108.4</td>
<td>$105.9</td>
<td>$108.4</td>
<td>$700.00</td>
<td>$227.6K</td>
<td align="right">604</td>
<td align="right">21</td>
</tr>
<tr>
<td>ASML</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$39.0</td>
<td>$38.4</td>
<td>$38.58</td>
<td>$640.00</td>
<td>$192.9K</td>
<td align="right">648</td>
<td align="right">100</td>
</tr>
<tr>
<td>ASML</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$89.7</td>
<td>$87.0</td>
<td>$89.7</td>
<td>$750.00</td>
<td>$188.3K</td>
<td align="right">95</td>
<td align="right">21</td>
</tr>
<tr>
<td>ASML</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$48.8</td>
<td>$48.5</td>
<td>$48.8</td>
<td>$700.00</td>
<td>$102.4K</td>
<td align="right">269</td>
<td align="right">23</td>
</tr>
<tr>
<td>ASML</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$27.4</td>
<td>$25.4</td>
<td>$25.4</td>
<td>$700.00</td>
<td>$93.9K</td>
<td align="right">932</td>
<td align="right">38</td>
</tr>
</tbody>
</table>

<h3>About ASML Holding</h3>
ASML is the leader in photolithography systems used in the manufacturing of semiconductors. Photolithography is the process in which a light source is used to expose circuit patterns from a photo mask onto a semiconductor wafer. The latest technological advances in this segment allow chipmakers to continually increase the number of transistors on the same area of silicon, with lithography historically representing a high portion of the cost of making cutting-edge chips. ASML outsources the manufacturing of most of its parts, acting like an assembler. ASML's main clients are TSMC, Samsung, and Intel.
Following our analysis of the options activities associated with ASML Holding, we pivot to a closer look at the company's own performance.
<h3>ASML Holding's Current Market Status</h3>
<ul>
<li>Trading volume stands at 482,394, with ASML's price down by -0.55%, positioned at $668.45.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 68 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest ASML Holding options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

ASML

ASML Holding's Options Frenzy: What You Need to Know

News

IPOs

CASK

Heritage Distilling Opens For Trade At $4/Share; IPO Priced At $4/Share On 1.6875M Shares

Oppenheimer analyst Mitchel Penn maintains Oaktree Specialty Lending (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCSL#NASDAQ">OCSL</a>) with a Perform and maintains $18 price target.

OCSL

Oppenheimer Maintains Perform on Oaktree Specialty Lending, Maintains $18 Price Target

QMMM

QMMM Shares Resume Trade

Nano Labs Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) shares rose on Friday after the company launched its second-generation<a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener"> V Series crypto mining products.</a>
Powered by the advanced Cuckoo 3.0 chips, the V2, V2H, and V2X models set new benchmarks for performance and energy <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42136093/nano-labs-launches-second-generation-v-series-with-5x-power-efficiency-boost" rel="noreferrer noopener">efficiency in the crypto-mining industry.</a>
The V2H and V2X models deliver nearly four times the computing power of their first-generation counterparts, significantly enhancing power efficiency.
This makes the V2 Series one of the most efficient mining solutions on the market. In addition to performance improvements, the V2 Series features upgraded hardware, enhanced heat dissipation systems, and better resistance to high temperatures, ensuring more stable and cost-effective operation.
Also Read:<a target="_blank" href="https://www.benzinga.com/news/econ-s/24/11/42138717/dollar-hits-2-year-highs-as-europes-recession-signals-spark-euro-pound-sell-offs" rel="noreferrer noopener"> Dollar Hits 2-Year High As European Recession Fears Hammer Euro, Pound</a>
Nano Labs, which began crypto mining chip design in 2022, initially launched the B1L product featuring the Darkbird 1.0 chip for BTC mining. This was followed by the first-generation V1 Series, powered by the Cuckoo 2.0 chip for ETH mining.
Recently, on November 18, Nano Labs received a notification letter from the Listing Qualifications Department of Nasdaq indicating that it has regained compliance with the <a target="_blank" href="https://www.benzinga.com//node/42075274" rel="noreferrer noopener">minimum bid price requirement.</a>
Also, earlier this week, Nano Labs revealed its intention to allocate some excess liquidity to Bitcoin and hold it as a <a target="_blank" href="https://www.benzinga.com//node/42034251" rel="noreferrer noopener">long-term strategic reserve asset.</a>
Price Action: NA shares are trading higher by 52.9% to $6.68 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42124676/november-small-cap-surge-could-carry-into-decembers-santa-rally-historical-trends-suggest" target="_blank" rel="noreferrer noopener">November Small-Cap Surge Could Carry Into December's Santa Rally, Historical Trends Suggest</a></li>
</ul>

Equities

General

Chinese Fabless Integrated Circuit Company Nano Labs Stock Skyrockets With New V Series Launch: Details

<a href="https://www.bloomberg.com/news/articles/2024-11-22/facebook-appeal-over-shareholder-suit-dropped-by-supreme-court">https://www.bloomberg.com/news/articles/2024-11-22/facebook-appeal-over-shareholder-suit-dropped-by-supreme-court</a>
&nbsp;
The US Supreme Court dismissed an appeal by <a href="https://www.bloomberg.com/quote/META:US">Meta Platforms Inc.</a>, leaving it to face a lawsuit that accuses the company of misleading shareholders about the data-harvesting scandal involving political consulting firm <a href="https://www.bloomberg.com/quote/1584842D:LN">Cambridge Analytica</a>.
Investors claim the company, then known as Facebook, inflated share prices by failing to adequately disclose the risk that its user data would be misused. The shareholders say revelations about the scandal contributed to two 2018 price drops that cost the company more than $200 billion in market value.

Legal

'Meta Must Face Investor Suit After Supreme Court Drops Case; Company Faces Allegations Over Data-Harvesting Scandal; Supreme Court Heard Arguments On Meta's Appeal On Nov. 6' - Bloomberg News

Trump Media &amp; Technology Group Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) boasts an 82.88% gain over the past year. Yet recent months have tested the resolve of its bulls, with a 30.17% dip over six months and a 9.45% slide <a href="https://www.benzinga.com/topic/donald-trump">in the last month</a>.
The Truth Social parent company is now exploring a cryptocurrency payment service, TruthFi, as <a href="https://www.ft.com/content/d7f921d5-3668-4b6b-a98d-2681ad73610f">reported</a> by the Financial Times. 
Is this the diversification move the stock needs to regain its upward momentum?
Read Also: <a href="https://www.benzinga.com/general/social-media/24/11/42124007/trump-media-trademark-filing-for-truthfi-hints-at-potential-digital-wallets-asset-trading">Trump Media Trademark Filing For &#8216;TruthFi&#8217; Hints At Potential Digital Wallets, Asset Trading</a>
<h2 class="wp-block-heading">DJT Stock Chart: Bulls &amp; Bears Playing Tug-O-War</h2>
DJT's technical indicators paint a mixed picture. 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22103058/Screenshot-2024-11-22-at-9.00.42-PM.png" alt="" class="wp-image-661165" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22103058/Screenshot-2024-11-22-at-9.00.42-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22103058/Screenshot-2024-11-22-at-9.00.42-PM-300x234.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112224&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
DJT stock, at $30.77, sits above its eight-day simple moving average (SMA) of $29.75, offering a short-term bullish signal. 
Yet, its 20-day SMA of $33.53 looms as a resistance point, giving a bearish signal. The 50-day SMA at $26.60 reinforces a bullish undertone for the intermediate term, but the 200-day SMA at $34.45 suggests broader bearish pressure.
Momentum indicators add complexity: the moving average convergence/divergence (MACD) indicator sits at 0.18, a bullish signal, while the relative strength index (RSI) at 50.16 hovers in neutral territory. 
DJT stock traders are likely watching closely for any confirmation of a breakout or breakdown from these levels.
<h2 class="wp-block-heading">TruthFi: Crypto Catalyst Or Diversification Dilemma?</h2>
Trump Media's trademark application for TruthFi hints at ambitions to leverage the crypto wave. If launched, TruthFi could extend beyond payment processing to include trading and asset management, positioning DJT as more than a social media play. The nascent nature of these plans — compounded by broader market skepticism — leaves the timeline and impact uncertain.
Trump Media is also reportedly interested in buying Bakkt. Shares of the crypto custody startup skyrocketed 160% on the rumors, but no concrete deal has materialized.
President-elect Donald Trump's signaling of crypto-friendly regulation will likely benefit DJT stock as well. 
<h2 class="wp-block-heading">What's Next For DJT Stock?</h2>
While bulls may see Trump Media's entry into crypto as the next growth catalyst, bears argue the stock's technical resistance and uncertain fundamentals warrant caution. 
For now, traders find themselves at an inflection point, waiting to see whether TruthFi's promise can materialize into profits — and whether DJT can move the needle in either direction.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42071926/a-hedge-fund-hit-big-on-trumps-rumored-crypto-acquisition-and-is-up-1415-million">A Hedge Fund Hit Big On Trump&#8217;s Rumored Crypto Acquisition And Could Be Up $14.15 Million</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Social Media

Technicals

Tech

Trump Media's TruthFi Gamble Tests Bulls And Bears

<a href="https://www.wsj.com/health/healthcare/sanofi-plans-to-change-hospital-drug-discount-program-18557f6d">https://www.wsj.com/health/healthcare/sanofi-plans-to-change-hospital-drug-discount-program-18557f6d</a>
&nbsp;
An industry fight against <a href="https://www.wsj.com/articles/340b-drug-discounts-hospitals-low-income-federal-program-11671553899?mod=article_inline&amp;mod=article_inline">lucrative drug discounts</a> for hospitals is intensifying as another drugmaker joins the battle: <a href="https://www.wsj.com/market-data/quotes/FR/XPAR/SAN">Sanofi</a>.
The pharmaceutical company plans to change its policy on how it gives discounts to certain hospitals. Sanofi will require institutions to provide pharmacy and medical claims information before receiving federally mandated discounts. The company plans to send a letter, which was reviewed by The Wall Street Journal, to hospitals outlining its new model on Friday, according to people familiar with the matter.&nbsp;

Biotech

'Sanofi Plans To Change Hospital Drug-Discount Program; French Company Looks To Rein In How It Gives Discounts In Federal Program Designed To Help Hospitals That Serve Low-income And Uninsured Patients' - WSJ

QMMM Shares Halted On Circuit Breaker To The Downside, Stock Now Up 30.3%

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler boosted the price target for Elastic N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) from $100 to $130. Piper Sandler analyst Rob Owens maintained an Overweight rating. Elastic shares closed at $109.21 on Thursday. <a href="https://www.benzinga.com/quote/ESTC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>RBC Capital cut the price target for Atkore Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATKR#NYSE">ATKR</a>) from $99 to $93. RBC Capital analyst Deane Dray maintained a Sector Perform rating. Atkore shares closed at $85.14 on Thursday. <a href="https://www.benzinga.com/quote/ATKR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan cut Warner Music Group Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NYSE">WMG</a>) price target from $41 to $40. JP Morgan analyst David Karnovsky maintained an Overweight rating. Warner Music shares settled at $31.18 on Thursday. <a href="https://www.benzinga.com/quote/WMG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc boosted Procore Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCOR#NYSE">PCOR</a>) price target from $68 to $85. Keybanc analyst Jason Celino maintained an Overweight rating. Procore Technologies shares closed at $75.23 on Thursday. <a href="https://www.benzinga.com/quote/PCOR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel cut DiamondRock Hospitality Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRH#NYSE">DRH</a>) price target from $10.75 to $10.25. Stifel analyst Simon Yarmak downgraded the stock from Buy to Hold. DiamondRock Hospitality shares closed at $9.14 on Thursday.  <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Benchmark cut PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) price target from $185 to $160. Benchmark analyst Fawne Jiang maintained a Buy rating. PDD shares closed at $104.09 on Thursday. See how other analysts view this stock.</li>
<li>Truist Securities raised the price target for AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) from $119 to $129. Truist Securities analyst Jamie Cook maintained a Buy rating. AECOM shares settled at $112.56 on Thursday. <a href="https://www.benzinga.com/quote/ACM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Oppenheimer boosted Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) price target from $712 to $722. Oppenheimer analyst Scott Schneeberger maintained an Outperform rating. Intuit shares closed at $678.70 on Thursday. <a href="https://www.benzinga.com/quote/INTU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclay increased the price target for The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) from $31 to $32. Barclays analyst Adrienne Yih maintained an Overweight rating. Gap shares closed at $22.04 on Thursday. <a href="https://www.benzinga.com/quote/GAP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel cut Spire Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SR#NYSE">SR</a>) price target from $70 to $69. Stifel analyst Selman Akyol maintained a Hold rating. Spire shares closed at $70.66 on Thursday. <a href="https://www.benzinga.com/quote/SR/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42139477/this-hca-healthcare-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-friday">This HCA Healthcare Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday</a></li>
</ul>

ATKR

ESTC

INTU

PCOR

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Gap To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Friday

Oppenheimer analyst Ken Wong maintains Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with a Outperform and raises the price target from $300 to $350.

ADSK

Oppenheimer Maintains Outperform on Autodesk, Raises Price Target to $350

Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) stock fell 1.7% to $162.87 this week, as investors assessed the ripple effects of NVIDIA's <a href="https://www.benzinga.com/markets/24/11/42101875/nvidia-beats-q3-revenue-eps-estimates-supply-constraints-ding-stock-huang-says-age-of-ai-is-in-full">third-quarter earnings report</a> on the broader semiconductor sector.
Nvidia, a key player in AI and data center markets where Broadcom also operates, posted strong results but provided a cautious fourth quarter outlook. The mixed market reaction to Nvidia&#8217;s report appeared to keep Broadcom shares in a holding pattern, reflecting broader uncertainties about growth prospects in the chip industry.
What To Know: Nvidia's robust performance underscored the ongoing demand for AI-related infrastructure, including advanced GPUs and complementary hardware, areas where Broadcom's networking and connectivity solutions play a critical role. 
<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42119226/nvidia-analysts-see-stock-best-positioned-in-ai-not-worried-about-guidance-all-systems-go-for-blackwell-ramp">Analysts highlighted</a> Nvidia's next-generation Blackwell architecture as a significant driver of demand through 2025. However, Nvidia's guidance falling short of lofty expectations caused some profit-taking, illustrating the market&#8217;s sensitivity to growth narratives in the AI space.
Read Also: <a href="https://www.benzinga.com/24/11/42137117/teslas-balancing-act-us-china-trade-tensions-what-it-means-for-tsla-stock">Tesla Gains 55% In A Month With Strong China Role, Bullish Signals</a>
Broadcom, a major supplier of chips for data centers and AI workloads, is often viewed as a complementary player to Nvidia, benefiting from the surge in demand for high-performance computing infrastructure. 
Investors have also been closely watching Broadcom's strategic moves in recent memory, particularly its ongoing diversification efforts, including its <a href="https://www.benzinga.com/m-a/24/07/39692197/broadcom-issues-5b-in-debt-to-fund-vmware-acquisition">$61 billion acquisition</a> of VMware. 
This deal could further strengthen Broadcom's position in software-defined infrastructure, enhancing its ability to serve hyperscale data centers.
While Nvidia&#8217;s earnings highlighted sector strength, it also raised questions about near-term growth pacing. For Broadcom, the focus remains on its ability to capture a share of this evolving demand while leveraging its diverse portfolio.
Read Also: <a href="https://www.benzinga.com/news/econ-s/24/11/42138717/dollar-hits-2-year-highs-as-europes-recession-signals-spark-euro-pound-sell-offs">Dollar Hits 2-Year High As European Recession Fears Hammer Euro, Pound</a>
<h2 class="wp-block-heading">How To Buy AVGO Stock?</h2>
By now you're likely curious about how to participate in the market for Broadcom &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, AVGO has a 52-week high of $186.42 and a 52-week low of $90.31.

AVGO

What's Going On With Broadcom (AVGO) Stock?

BMO Capital analyst Thanos Moschopoulos maintains Real Matters (TSX:<a class="ticker" href="https://www.benzinga.com/stock/REAL#TSX">REAL</a>) with a Market Perform and lowers the price target from C$7.5 to C$7.

TSX:REAL

BMO Capital Maintains Market Perform on Real Matters, Lowers Price Target to C$7

Trading Halt: Halt status updated at 11:25:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

RBC Capital analyst Ben Hendrix reiterates SelectQuote (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLQT#NYSE">SLQT</a>) with a Sector Perform and maintains $4 price target.

SLQT

RBC Capital Reiterates Sector Perform on SelectQuote, Maintains $4 Price Target

BMO Capital analyst Jeffrey Silber maintains KinderCare Learning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLC#NYSE">KLC</a>) with a Outperform and lowers the price target from $34 to $31.

BMO Capital Maintains Outperform on KinderCare Learning, Lowers Price Target to $31

Nomura analyst Bing Duan upgrades Kingsoft Cloud Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) from Neutral to Buy and raises the price target from $2.3 to $6.7.

Upgrades

Nomura Upgrades Kingsoft Cloud Hldgs to Buy, Raises Price Target to $6.7

BMO Capital analyst Evan David Seigerman maintains Replimune Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) with a Outperform and raises the price target from $14 to $18.

REPL

BMO Capital Maintains Outperform on Replimune Group, Raises Price Target to $18

Shuttle Pharma regains compliance with Nasdaq minimum bid price requirement

Shuttle Pharmaceuticals files for offering common stock, warrants

An announcement from Shuttle Pharmaceuticals Holdings, Inc. ( ($SHPH) ) is now available. Shuttle Pharmaceuticals Holdings is set to present at the...

Shuttle Pharmaceuticals to Present at ThinkEquity Conference

Shuttle Pharmaceuticals Holdings, Inc. ( ($SHPH) ) just unveiled an update. Shuttle Pharmaceuticals Holdings has finalized agreements with six canc...

Shuttle Pharmaceuticals Advances Glioblastoma Clinical Trials

Shuttle Pharmaceuticals (SHPH) Holdings announced it has finalized agreements with all six of the planned site enrollment locations to administer t...

Shuttle's clinical trial site enrollments complete for Phase 2 of IPdR for GBM

Shuttle Pharmaceuticals (SHPH) announced that the first three patients in its Phase 2 Clinical Trial of Ropidoxuridine for the treatment of patient...

Shuttle Pharmaceuticals doses first patients in Phase 2 trial of Ropidoxuridine

Shuttle Pharmaceuticals Holdings, Inc. ( ($SHPH) ) has issued an announcement. Shuttle Pharmaceuticals has announced the successful dosing of the f...

Shuttle Pharmaceuticals Advances Phase 2 Glioblastoma Trial

Shuttle Pharmaceuticals (SHPH) announced the pricing of its "reasonable best efforts" public offering with a health-care focused institutional inve...

Comments

Shuttle Pharmaceuticals

Shuttle Pharmaceuticals (SHPH) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL